Search - tctmd.com

Displaying 121 - 140 of 152

Sort: Relevancy | Date

News Daily News

Drug-Eluting Balloons Reduce Restenosis, TLR in Diabetic Patients with CLI

Yael L. Maxwell

February 26, 2014

Presentation TCT 2013

RIBS IV-ISR Trial: Background and Trial Design

Presenter: Fernando Alfonso

October 31, 2013

Presentation TCT 2013

PEPCAD-China ISR Trial: 9-Month Angiographic and 1-Year Clinical Results

Presenter: Junbo Ge

October 31, 2013

Presentation TCT 2013

Critical Review of Drug-Coated Balloon Data for the Coronary ISR Application

Presenter: Bruno Scheller

October 31, 2013

Presentation TCT 2013

Angiosculpt DCB-ISR Trial

Presenter: Alexandre Abizaid

October 31, 2013

Presentation TCT 2013

TCT-56. PEPCAD China ISR: A Prospective, Multicenter, Randomized Trial of Paclitaxel-Coated Balloon versus Paclitaxel-Eluting Stent for the Treatment of DES In-Stent Restenosis ...

Presenter: Bo Xu

October 29, 2013

News Daily News

Contemporary ZES Perform Well in Treating In-Stent Restenosis

August 14, 2013

News Conference News EuroPCR 2013

EuroPCR 2013: From Cutting-Edge Devices to the Clinical Challenges

Caitlin E. Cox

May 29, 2013

Presentation EuroPCR 2013

PEPCAD China ISR

Presenter: Run-Lin Gao

May 23, 2013

News Conference News EuroPCR 2013

Paclitaxel-eluting Balloon Matches Taxus for Treating DES Restenosis

Jason Kahn

May 23, 2013

News Daily News

Most Deaths Within 30 Days After PCI Not a Direct Result of Procedure

Caitlin E. Cox

May 13, 2013

News Daily News

La Mayoría de Muertes 30 Días Después de una PCI No son Resultado Directo de la Intervención

Caitlin E. Cox

May 13, 2013

News Daily News

ISAR-DESIRE 3 Published: Paclitaxel-Eluting Balloons Match PES for DES Restenosis

Caitlin E. Cox

February 07, 2013

Presentation TCT 2013

Efficacy and Safety of Drug-Eluting Balloon Compared to Drug-Eluting Stent for The Treatment of In-Stent Restenosis (ISR)

Presenter: Myung-Hyun Kim, Byeong-Keuk Kim

January 31, 2013

Presentation TCT 2013

Comparison Of Long-term Outcomes With Everolimus-Eluting- and Sirolimus-Eluting Stents In Small Coronary Artery Disease

Presenter: Hironori Kitabata, Joshua Loh, Gabriel Sardi, Salem Badr, Danny Dvir, Israel Barbash, Rebecca Torguson, Kenneth Kent, Lowell Satler, William Suddath, Augusto Pichard, Ron Waksman

January 31, 2013

News Daily News

Un Nuevo Anti Inflamatorio podría Reducir la Estenosis tras la Implantación de SMD en Pacientes de Alto Riesgo

L.A. McKeown

January 13, 2013

News Daily News

Novel Anti-inflammatory May Reduce Restenosis After BMS in High-Risk Patients

L.A. McKeown

January 13, 2013

Presentation TCT 2012

From IMPACT-ISR to BELLO: Urea-Based PCB Coating (Invatec)

Presenter: Antonio Colombo

October 25, 2012

Presentation TCT 2012

Coronary ISR: An Accepted Clinical Indication in the DES World?

Presenter: Huay Cheem Tan

October 25, 2012

News Daily News

Los Balones liberadores de Fármacos arrojan Resultados Positivos en el Tratamiento de la Reestenosis intra stent

Jason Kahn

October 05, 2012

Advertisement

Drug-Eluting Balloons Reduce Restenosis, TLR in Diabetic Patients with CLI

RIBS IV-ISR Trial: Background and Trial Design

PEPCAD-China ISR Trial: 9-Month Angiographic and 1-Year Clinical Results

Critical Review of Drug-Coated Balloon Data for the Coronary ISR Application

Angiosculpt DCB-ISR Trial

TCT-56. PEPCAD China ISR: A Prospective, Multicenter, Randomized Trial of Paclitaxel-Coated Balloon versus Paclitaxel-Eluting Stent for the Treatment of DES In-Stent Restenosis ...

Contemporary ZES Perform Well in Treating In-Stent Restenosis

EuroPCR 2013: From Cutting-Edge Devices to the Clinical Challenges

PEPCAD China ISR

Paclitaxel-eluting Balloon Matches Taxus for Treating DES Restenosis

Most Deaths Within 30 Days After PCI Not a Direct Result of Procedure

La Mayoría de Muertes 30 Días Después de una PCI No son Resultado Directo de la Intervención

ISAR-DESIRE 3 Published: Paclitaxel-Eluting Balloons Match PES for DES Restenosis

Efficacy and Safety of Drug-Eluting Balloon Compared to Drug-Eluting Stent for The Treatment of In-Stent Restenosis (ISR)

Comparison Of Long-term Outcomes With Everolimus-Eluting- and Sirolimus-Eluting Stents In Small Coronary Artery Disease

Un Nuevo Anti Inflamatorio podría Reducir la Estenosis tras la Implantación de SMD en Pacientes de Alto Riesgo

Novel Anti-inflammatory May Reduce Restenosis After BMS in High-Risk Patients

From IMPACT-ISR to BELLO: Urea-Based PCB Coating (Invatec)

Coronary ISR: An Accepted Clinical Indication in the DES World?

Los Balones liberadores de Fármacos arrojan Resultados Positivos en el Tratamiento de la Reestenosis intra stent

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content